Key Points
- CEO Robert Mauch sold 5,096 shares for $1,807,704.08, reducing his ownership by 7.10% to 66,726 shares valued at about $23.67 million.
- Cencora beat Q results modestly (EPS $3.84 vs. $3.79) with revenue up 5.9% to $83.73 billion and issued FY2026 guidance of 17.45–17.75 EPS, while analysts hold a consensus "Moderate Buy" with a $393.08 target.
- The company increased its quarterly dividend to $0.60 (annualized $2.40), implying a ~0.7% yield and a payout ratio around 30%.
Cencora, Inc. (NYSE:COR - Get Free Report) CEO Robert Mauch sold 5,096 shares of the firm's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares of the company's stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Cencora Stock Up 0.2%
COR opened at $352.30 on Friday. The company has a market capitalization of $68.34 billion, a P/E ratio of 44.31, a P/E/G ratio of 1.67 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm's fifty day moving average price is $348.66 and its two-hundred day moving average price is $321.55. Cencora, Inc. has a fifty-two week low of $237.71 and a fifty-two week high of $377.54.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts' consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the firm earned $3.34 EPS. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora's previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora's dividend payout ratio (DPR) is presently 30.19%.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Atlantic Edge Private Wealth Management LLC grew its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company's stock worth $25,000 after acquiring an additional 35 shares during the last quarter. IAG Wealth Partners LLC acquired a new position in shares of Cencora during the third quarter worth approximately $30,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company's stock valued at $31,000 after purchasing an additional 43 shares during the last quarter. Cloud Capital Management LLC acquired a new stake in shares of Cencora in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC acquired a new stake in shares of Cencora in the third quarter valued at approximately $31,000. 97.52% of the stock is owned by institutional investors.
Analyst Ratings Changes
COR has been the topic of several recent analyst reports. Wall Street Zen lowered Cencora from a "buy" rating to a "hold" rating in a research note on Friday, November 28th. Weiss Ratings reissued a "hold (c+)" rating on shares of Cencora in a report on Monday, December 29th. UBS Group boosted their target price on shares of Cencora from $380.00 to $415.00 and gave the company a "buy" rating in a research note on Friday, November 7th. Jefferies Financial Group upgraded shares of Cencora from an "underperform" rating to a "buy" rating in a research report on Thursday. Finally, Mizuho lifted their price target on shares of Cencora from $340.00 to $380.00 and gave the company an "outperform" rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $393.08.
Read Our Latest Research Report on COR
About Cencora
(
Get Free Report)
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
